HRP20230538T1 - Rekombinantne virusne čestice s modificiranim tropizmom i njihove upotrebe za ciljano uvođenje genetičkog materijala u humane stanice - Google Patents
Rekombinantne virusne čestice s modificiranim tropizmom i njihove upotrebe za ciljano uvođenje genetičkog materijala u humane stanice Download PDFInfo
- Publication number
- HRP20230538T1 HRP20230538T1 HRP20230538TT HRP20230538T HRP20230538T1 HR P20230538 T1 HRP20230538 T1 HR P20230538T1 HR P20230538T T HRP20230538T T HR P20230538TT HR P20230538 T HRP20230538 T HR P20230538T HR P20230538 T1 HRP20230538 T1 HR P20230538T1
- Authority
- HR
- Croatia
- Prior art keywords
- capsid protein
- targeting ligand
- viral capsid
- target cell
- cell
- Prior art date
Links
- 230000003612 virological effect Effects 0.000 title claims 40
- 102000004169 proteins and genes Human genes 0.000 title claims 21
- 108090000623 proteins and genes Proteins 0.000 title claims 21
- 239000002245 particle Substances 0.000 title claims 9
- 210000005260 human cell Anatomy 0.000 title 1
- 108090000565 Capsid Proteins Proteins 0.000 claims 42
- 102100023321 Ceruloplasmin Human genes 0.000 claims 42
- 239000003446 ligand Substances 0.000 claims 35
- 230000008685 targeting Effects 0.000 claims 35
- 210000004027 cell Anatomy 0.000 claims 33
- 230000027455 binding Effects 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 241000700605 Viruses Species 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 150000001413 amino acids Chemical group 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 4
- 210000002569 neuron Anatomy 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 3
- 101150044789 Cap gene Proteins 0.000 claims 3
- 101150029707 ERBB2 gene Proteins 0.000 claims 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 3
- 210000000234 capsid Anatomy 0.000 claims 3
- 108010047482 ectoATPase Proteins 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 230000010415 tropism Effects 0.000 claims 3
- 102000005427 Asialoglycoprotein Receptor Human genes 0.000 claims 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 2
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 2
- 102100025222 CD63 antigen Human genes 0.000 claims 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 2
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 claims 2
- 101001040075 Homo sapiens Glucagon receptor Proteins 0.000 claims 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 2
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims 2
- 101000835086 Homo sapiens Transferrin receptor protein 2 Proteins 0.000 claims 2
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims 2
- 102100026143 Transferrin receptor protein 2 Human genes 0.000 claims 2
- 108010006523 asialoglycoprotein receptor Proteins 0.000 claims 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 210000003292 kidney cell Anatomy 0.000 claims 2
- 210000005229 liver cell Anatomy 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 241001655883 Adeno-associated virus - 1 Species 0.000 claims 1
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims 1
- 241000202702 Adeno-associated virus - 3 Species 0.000 claims 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 claims 1
- 241001634120 Adeno-associated virus - 5 Species 0.000 claims 1
- 241000972680 Adeno-associated virus - 6 Species 0.000 claims 1
- 241001164823 Adeno-associated virus - 7 Species 0.000 claims 1
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims 1
- 108010002913 Asialoglycoproteins Proteins 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 102100029725 Ectonucleoside triphosphate diphosphohydrolase 3 Human genes 0.000 claims 1
- 101710116097 Ectonucleoside triphosphate diphosphohydrolase 3 Proteins 0.000 claims 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 claims 1
- 108010033576 Transferrin Receptors Proteins 0.000 claims 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 210000000663 muscle cell Anatomy 0.000 claims 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
- C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Claims (28)
1. Rekombinantni virusni protein kapsida koji je genetički modificiran da izrazi heterolognu sekvencu aminokiselina koja sadrži prvi član vezujućeg para protein:protein umetnut u protein virusnog kapsida ,
pri čemu je protein virusnog kapsida dobiven iz cap gena adeno-povezanog virusa (AAV) koji kodira AAV VP1, VP2, i/ili VP3 protein kapsida; pri čemu:
(a) prvi član vezujućeg para protein:protein je peptidni tag i sposoban je za obrazovanje izopeptidne veze s drugim srodnim članom protein:protein veznog para; ili
(b) prvi član veznog para protein:protein je peptidni tag i protein virusa kapsida dalje sadrži drugi srodni član veznog para protein:protein, pri čemu prvi član i drugi srodni član su vezani izopeptidnom vezom.
2. Rekombinantni protein virusnog kapsida prema zahtjevu 1, pri čemu protein virusa kapsida dalje sadrži drugi srodni član veznog para protein:protein, pri čemu su prvi član i drugi srodni član vezani izopeptidnom vezom.
3. Rekombinantni protein virusnog kapsida prema zahtjevu 1 ili zahtjevu 2, pri čemu je protein virusnog kapsida dobiven iz himernog (kimernog?)AAV cap gena.
4. Rekombinantni protein virusnog kapsida prema bilo kojem od prethodnih zahtejva, gdje virusni protein kapsida dalje sadrži mutaciju pored prvog člana veznog para protein:protein.
5. Rekombinantni protein virusnog kapsida prema bilo kojem od prethodnih zahtjeva, pri čemu:
(a) prvi član smanjuje ili ukida prirodni tropizam proteina kapsida; i/ili
(b) virusni protein kapsida dalje sadrži mutaciju pored prvog člana veznog para protein:protein, koja smanjuje ili ukida prirodni tropizam proteina kapsida.
6. Rekombinantni protein virusnog kapsida prema bilo kojem od prethodnih zahtjeva, pri čemu:
(a) bočno s obje strane prvog člana je prvi i/ili drugi povezivač koji spaja prvi član s proteinom kapsida virusa, i gdje je prvi i/ili drugi povezivač svaki nezavisno dužine bar jedne aminokiseline;
(b) protein virusnog kapsida koji dalje sadrži mutaciju na poziciji aminokiseline uključenu u vezivanje proteina virusa kapsida s njegovim prirodnim receptorom, pri čemu mutacija sadrži inserciju heterolognog peptida u protein kapsida, zamjenu jedne ili više aminokiselina u proteinu kapsida s heterolognim peptidom, brisanje jedne ili više aminokiselina u proteinu kapsida, ili njihovu kombinaciju;
(c) AAV je odabran iz grupe koja se sastoji iz AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8 i AAV9;
(d) vezni par protein:protein je:
(i) SpyTag: SpyCatcher,
(ii) SpyTag:KTag,
(iii) Izopeptag:pilin-C,
(iv) SnoopTag: SnoopCatcher,
(v) SpyTag002:SpyCatcher002; ili
(e) bilo koja kombinacija (a)-(d).
7. Rekombinantni protein virusnog kapsida prema zahtjevu 5 ili 6, pri čemu je tropizam proteina virusnog kapsida:
(a) obnovljen;
(b) preusmjeren; ili
(c) obnovljen i preusmjeren,
nakon obrazovanja izopeptidne veze s drugim srodnim članom, pri čemu je drugi srodni član spojen s a ligandom za ciljanje koji specifično veže ciljnu stanicu.
8. Rekombinantni protein virusnog kapsida prema bilo kom od zahtjeva 2-7, pri čemu:
(a) prvi član je SpyTag i drugi srodni član je SpyCatcher ili KTag;
(b) prvi član je KTag i drugi srodni član je SpyTag;
(c) prvi član je SnoopTag i drugi srodni član je SnoopCatcher;
(d) prvi član je isopeptag i drugi srodni član je Pilin-C; ili
(e) prvi član je SpyTag002 i drugi srodni član je SpyCatcher002.
9. Rekombinantni protein virusnog kapsida prema bilo kojem od zahtjeva 2-7, pri čemu je drugi srodni član vezan s ligandom za ciljanje.
10. Rekombinantni protein virusnog kapsida prema zahtjevu 9, gdje:
(a) ligand za ciljanje je ostatak za vezanje;
(b) ligand za ciljanje je antitijelo, ili njegov dio;
(c) ligandom za ciljanje sadrži aminokiselinsku sekvencu prikazanu u SEQ ID NO:46;
(d) ligandom za ciljanje specifično veže molekulu stanične površine; ili
(e) bilo koja kombinacija pod (a)-(d).
11. Rekombinantni protein virusnog kapsida prema zahtjevu 10, pri čemu je ostatak za vezanje antitijelo, ili njegov dio, gdje:
(a) antitijelo, ili njegov dio, je spojeno sa SpyCatcher;
(b) antitijelo, ili njegov dio, je spojeno sa SpyCatcher, pri čemu antitijelo, ili njegov dio, je spojeno s povezivačem na C-terminusu, i povezivač je spojen s SpyCatcher na C-kraju povezivača; ili
(c) antitijelo, ili njegov dio, je spojen s SpyCatcher, pri čemu antitijelo, ili njegov dio, je spojen s povezivačem na C-kraju, i povezivač je spojen s SpyCatcher na C-kraju povezivača, pri čemu povezivač sadrži sekvencu prikazanu u SEQ ID NO:48 (GSGESG).
12. Rekombinantni protein virusnog kapsida prema zahtjevu 10, pri čemu ligand za ciljanje specifično veže molekulu stanične površine koji je:
(i) asijaloglikoprotein 1 (ASGR1),
(ii) humana ektonukleozid trifosfat difosfohidrolaza 3 (ENTPD3),
(iii) PTPRN,
(iv) CD20,
(v) CD63,
(vi) Her2; ili
(vii) receptor 2 transferina.
13. Rekombinantni protein virusnog kapsida prema zahtjevu 10, pri čemu:
(a) ligand za ciljanje specifično veže molekulu koju eksprimira neuronska stanica; ili
(b) ligand za ciljanje specifično veže receptor transferina koji eksprimira neuronska stanica.
14. Rekombinantni protein virusnog kapsida prema zahtjevu 10, pri čemu ligand za ciljanje specifično veže molekulu koja eksprimira mišićna stanica.
15. Rekombinantni virusni kapsid koji sadrži protein virusnog kapsida prema bilo kojem od zahtjeva 1-14.
16. Rekombinantni virusni kapsid prema zahtjevu 15, pri čemu protein virusnog kapsida dalje sadrži referentni protein virusnog kapsida kojem nedostaje bilo koji član specifičnog veznog para.
17. Rekombinantni virusni kapsid prema zahtjevu 16, koji sadrži protein virusnog kapsida i referentni protein virusnog kapsida u odnosu između 1: 1 i 1: 15.
18. Rekombinantna virusna čestica koja sadrži nukleotid od interesa inkapsuliran virusnim kapsidnim proteinom prema bilo kojem od zahtjeva 15-17.
19. Kompozicija koja sadrži: (a) protein virusnog kapsida prema bilo kojem od zahtjeva 15-17 ili česticu virusa prema zahtjevu 18; i (b) farmaceutski prihvatljiv nosač.
20. Čestica virusa prema zahtjevu 18 ili sastav prema zahtjevu 19 za upotrebu u postupku isporuke nukleotida od interesa u ciljnu stanicu koji obuhvaća dovođenje u kontakt ciljne stanice s spomenutom česticom virusa ili spomenutim sastavom, pri čemu protein virusnog kapsida sadrži ligand za ciljanje koji specifično veže protein eksprimiran na površini ciljne stanice.
21. Čestica virusa ili kompozicija za upotrebu u postupku prema zahtjevu 20, pri čemu:
(a) ciljna stanica je in vivo u subjektu;
(b) ciljna stanica je in vivo u humanom subjektu; i/ili
(c) ciljna stanica je humana ciljna stanica.
22. Čestica virusa ili kompozicija za upotrebu u postupku prema zahtjevu 21, pri čemu:
(i) ciljna stanica je humana stanica jetre, i pri čemu se ligand za ciljanje veže za humani asijaloglikoproteinski receptor (ASGR1);
(ii) ciljna stanica je humana neuronska stanica, i pri čemu ligand za ciljanje veže GABA;
(iii) ciljna stanica je humana T stanica, i pri čemu ligand za ciljanje veže CD3;
(iv) ciljna stanica je humana T stanica, i pri čemu ligand za ciljanje veže CD3ε;
(v) ciljna stanica je humana hematopoetska stanica, i pri čemu ligand za ciljanje veže CD34;
(vi) ciljna stanica je humana stanica bubrega;
(vii) ciljna stanica je humana stanica karcinoma, i pri čemu ligand za ciljanje veže antigen povezan s tumorom; ili
(viii) ciljna stanica je humana stanica karcinoma, i pri čemu ligand za ciljanje veže antigen povezan s tumorom, u kojem je tumorski antigen E6, E7 ili Her2.
23. Čestica virusa ili sastav za upotrebu u postupku prema zahtjevu 21, pri čemu:
(i) ligand za ciljanje veže PTPRN (Receptor protein tirozin fosfataze tipa N);
(ii) ligand za ciljanje veže CD20;
(iii) ligand za ciljanje veže za humani glukagonski receptor; ili
(iv) ligand za ciljanje specifično veže CD63 ili humanu ektonukleozid trifosfat difosfohidrolazu 3 (hENTPD3).
24. Postupak za isporuku nukleotida od interesa u in vitro ciljnu stanicu koji obuhvaća dovođenje u kontakt ciljne stanice s česticom virusa iz zahtjeva 18 ili sastava iz zahtjeva 19, pri čemu protein virusnog kapsida sadrži ligand za ciljanje koji specifično veže protein eksprimiran na površini ciljne stanice.
25. Postupak prema zahtjevu 24, u kojem:
(i) ciljna stanica je humana stanica jetre, i pri čemu se ligand za ciljanje veže za humani asialoglikoproteinski receptor (ASGR1);
(ii) ciljna stanica je humana neuronska stanica, i pri čemu se ligand za ciljanje veže za GABA;
(iii) ciljna stanica je humana T stanica, i pri čemu se ligand za ciljanje veže za CD3;
(iv) ciljna stanica je humana T stanica, i pri čemu se ligand za ciljanje veže za CD3ε;
(v) ciljna stanica je humana hematopoetska stanica, i pri čemu se ligand za ciljanje veže za CD34;
(vi) ciljna stanica je humana stanica bubrega;
(vii) ciljna stanica je humana stanica karcinoma, i pri čemu ligand za ciljanje veže antigen povezan s tumorom; ili
(viii) ciljna stanica je humana stanica karcinoma, i pri čemu ligand za ciljanje veže antigen povezan s tumorom, u kojem je tumorski antigen E6, E7 ili Her2.
26. Postupak prema zahtjevu 24, u kojem:
(i) ligand za ciljanje veže PTPRN;
(ii) ligand za ciljanje veže CD20;
(iii) ligand za ciljanje veže humani receptor glukagona; ili
(iv) ligand za ciljanje specifično veže CD63hENTPD3; ili
(v) ligand za ciljanje specifično veže receptor 2 transferina.
27. Rekombinantni vektor koji kodira protein virusnog kapsida prema bilo kojem od zahtjeva 1-14.
28. Gen cap AAV koji kodira rekombinantni protein virusnog kapsida prema bilo kojem od zahtjeva 1-14.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762525708P | 2017-06-27 | 2017-06-27 | |
| EP18749636.9A EP3645553B1 (en) | 2017-06-27 | 2018-06-27 | Tropism-modified recombinant viral particles and uses thereof for the targeted introduction of genetic material into human cells |
| PCT/US2018/039878 WO2019006046A2 (en) | 2017-06-27 | 2018-06-27 | RECOMBINANT VIRAL PARTICLES WITH MODIFIED TROPISM AND USES THEREOF FOR TARGETED INTRODUCTION OF GENETIC MATERIAL INTO HUMAN CELLS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230538T1 true HRP20230538T1 (hr) | 2023-08-04 |
Family
ID=63080488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230538TT HRP20230538T1 (hr) | 2017-06-27 | 2018-06-27 | Rekombinantne virusne čestice s modificiranim tropizmom i njihove upotrebe za ciljano uvođenje genetičkog materijala u humane stanice |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20200140492A1 (hr) |
| EP (2) | EP4219529A1 (hr) |
| JP (2) | JP2020525020A (hr) |
| KR (1) | KR20200021987A (hr) |
| CN (2) | CN110997699A (hr) |
| AU (2) | AU2018290885B2 (hr) |
| BR (1) | BR112019027866A2 (hr) |
| CA (1) | CA3066950A1 (hr) |
| CL (2) | CL2019003843A1 (hr) |
| CO (1) | CO2019014684A2 (hr) |
| CY (1) | CY1126149T1 (hr) |
| DK (1) | DK3645553T3 (hr) |
| ES (1) | ES2943020T3 (hr) |
| FI (1) | FI3645553T3 (hr) |
| HR (1) | HRP20230538T1 (hr) |
| HU (1) | HUE061908T2 (hr) |
| IL (1) | IL271570A (hr) |
| LT (1) | LT3645553T (hr) |
| MA (1) | MA49514B1 (hr) |
| MD (1) | MD3645553T2 (hr) |
| MX (1) | MX2020000246A (hr) |
| PH (1) | PH12019550269A1 (hr) |
| PL (1) | PL3645553T3 (hr) |
| PT (1) | PT3645553T (hr) |
| RS (1) | RS64233B1 (hr) |
| SG (1) | SG11201911614XA (hr) |
| SI (1) | SI3645553T1 (hr) |
| WO (1) | WO2019006046A2 (hr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10577627B2 (en) | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
| CN112041451B (zh) * | 2018-02-28 | 2024-03-08 | 匹兹堡大学联邦系统高等教育 | 基于aav的基因和蛋白质递送模块化系统 |
| CN111954683A (zh) | 2018-04-05 | 2020-11-17 | 生物辐射Abd瑟罗泰克有限公司 | 感兴趣的蛋白质的展示系统 |
| AU2020243460A1 (en) * | 2019-03-18 | 2021-10-07 | Bio-Rad Abd Serotec Gmbh | Protection of SpyTag-containing periplasmic fusion proteins from protease Tsp and ompT degradation |
| SG11202112917PA (en) | 2019-05-24 | 2021-12-30 | Regeneron Pharma | Modified viral particles and uses thereof |
| US20220306955A1 (en) * | 2019-06-11 | 2022-09-29 | Chevron U.S.A. Inc. | Membranes for contaminant removal from natural gas and methods for use thereof |
| GB201915905D0 (en) * | 2019-11-01 | 2019-12-18 | Spybiotech Ltd | Viruses with modified capsid proteins |
| EP4055034A1 (en) * | 2019-11-08 | 2022-09-14 | President And Fellows Of Harvard College | Viral capsid polypeptides |
| CN114632148A (zh) * | 2020-12-15 | 2022-06-17 | 榕森生物科技(北京)有限公司 | 病原样抗原疫苗及其制备方法 |
| CN114634578B (zh) * | 2020-12-15 | 2024-04-02 | 榕森生物科技(北京)有限公司 | 针对新型冠状病毒感染的疫苗组合物 |
| CA3233698A1 (en) | 2021-11-04 | 2023-05-11 | Regeneron Pharmaceuticals, Inc. | Viral particles retargeted to skeletal muscle |
| CN114213505B (zh) * | 2021-12-10 | 2022-09-20 | 和元生物技术（上海）股份有限公司 | 一种适用于特异感染u87-mg细胞的腺相关病毒突变体 |
| WO2023220603A1 (en) | 2022-05-09 | 2023-11-16 | Regeneron Pharmaceuticals, Inc. | Vectors and methods for in vivo antibody production |
| WO2023240124A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Pseudotyped viral particles for targeting tcr-expressing cells |
| WO2024026494A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Viral particles retargeted to transferrin receptor 1 |
| CN117723749A (zh) * | 2024-02-07 | 2024-03-19 | 南昌大学 | 基于分子粘合剂的动态光散射免疫传感检测方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1286981C (zh) * | 2004-11-30 | 2006-11-29 | 华中科技大学同济医学院附属同济医院 | 表达人类cyp2j2反义基因的重组腺相关病毒及其制备方法 |
| US20100203083A1 (en) | 2007-05-31 | 2010-08-12 | Medigene Ag | Mutated structural protein of a parvovirus |
| SG181477A1 (en) | 2009-12-10 | 2012-07-30 | Regeneron Pharma | Mice that make heavy chain antibodies |
| GB201002362D0 (en) | 2010-02-11 | 2010-03-31 | Isis Innovation | Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds |
| US9180185B2 (en) | 2013-01-11 | 2015-11-10 | Hoffman-La Roche Inc. | Combination therapy of anti-HER3 antibodies |
| KR102601491B1 (ko) | 2014-03-21 | 2023-11-13 | 리제너론 파마슈티칼스 인코포레이티드 | 단일 도메인 결합 단백질을 생산하는 비-인간 동물 |
| US20160018835A1 (en) * | 2014-07-18 | 2016-01-21 | Retroficiency, Inc. | System and method for virtual energy assessment of facilities |
| AU2016207099C1 (en) * | 2015-01-15 | 2021-02-04 | University Of Copenhagen | Virus-like particle with efficient epitope display |
| EP3262063B1 (en) | 2015-02-26 | 2021-09-22 | Var2 Pharmaceuticals ApS | Immunotherapeutic targeting of placental-like chondroitin sulfate using chimeric antigen receptors (cars) and immunotherapeutic targeting of cancer using cars with split-protein binding systems |
| EP3141600A1 (en) | 2015-09-11 | 2017-03-15 | Institut National de la Recherche Agronomique | Nepovirus coat protein fusion polypeptides and their use |
| KR20190065251A (ko) | 2016-08-18 | 2019-06-11 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 모듈러 AAV 전달 시스템을 통한 CRISPR-Cas 게놈 가공 |
| CN112041451B (zh) * | 2018-02-28 | 2024-03-08 | 匹兹堡大学联邦系统高等教育 | 基于aav的基因和蛋白质递送模块化系统 |
-
2018
- 2018-06-27 KR KR1020207001284A patent/KR20200021987A/ko not_active Application Discontinuation
- 2018-06-27 US US16/625,207 patent/US20200140492A1/en active Pending
- 2018-06-27 JP JP2019572025A patent/JP2020525020A/ja active Pending
- 2018-06-27 CA CA3066950A patent/CA3066950A1/en active Pending
- 2018-06-27 SI SI201830908T patent/SI3645553T1/sl unknown
- 2018-06-27 HU HUE18749636A patent/HUE061908T2/hu unknown
- 2018-06-27 BR BR112019027866-4A patent/BR112019027866A2/pt unknown
- 2018-06-27 PL PL18749636.9T patent/PL3645553T3/pl unknown
- 2018-06-27 CN CN201880054254.8A patent/CN110997699A/zh active Pending
- 2018-06-27 MX MX2020000246A patent/MX2020000246A/es unknown
- 2018-06-27 FI FIEP18749636.9T patent/FI3645553T3/fi active
- 2018-06-27 SG SG11201911614XA patent/SG11201911614XA/en unknown
- 2018-06-27 EP EP23153644.2A patent/EP4219529A1/en active Pending
- 2018-06-27 LT LTEPPCT/US2018/039878T patent/LT3645553T/lt unknown
- 2018-06-27 DK DK18749636.9T patent/DK3645553T3/da active
- 2018-06-27 MA MA49514A patent/MA49514B1/fr unknown
- 2018-06-27 RS RS20230411A patent/RS64233B1/sr unknown
- 2018-06-27 HR HRP20230538TT patent/HRP20230538T1/hr unknown
- 2018-06-27 AU AU2018290885A patent/AU2018290885B2/en active Active
- 2018-06-27 WO PCT/US2018/039878 patent/WO2019006046A2/en unknown
- 2018-06-27 EP EP18749636.9A patent/EP3645553B1/en active Active
- 2018-06-27 PT PT187496369T patent/PT3645553T/pt unknown
- 2018-06-27 MD MDE20200493T patent/MD3645553T2/ro unknown
- 2018-06-27 ES ES18749636T patent/ES2943020T3/es active Active
- 2018-06-27 CN CN202310837502.9A patent/CN116891534A/zh active Pending
-
2019
- 2019-12-09 PH PH12019550269A patent/PH12019550269A1/en unknown
- 2019-12-19 IL IL271570A patent/IL271570A/en unknown
- 2019-12-24 CO CONC2019/0014684A patent/CO2019014684A2/es unknown
- 2019-12-26 CL CL2019003843A patent/CL2019003843A1/es unknown
-
2020
- 2020-12-30 CL CL2020003438A patent/CL2020003438A1/es unknown
-
2022
- 2022-10-27 JP JP2022172414A patent/JP2022186991A/ja active Pending
-
2023
- 2023-06-14 CY CY20231100276T patent/CY1126149T1/el unknown
- 2023-07-12 AU AU2023204611A patent/AU2023204611A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230538T1 (hr) | Rekombinantne virusne čestice s modificiranim tropizmom i njihove upotrebe za ciljano uvođenje genetičkog materijala u humane stanice | |
| CN114127089A (zh) | 重组腺相关病毒及其用途 | |
| ES2857773T3 (es) | Nuevas proteínas de la cápside de AAV para la transferencia de ácidos nucleicos | |
| US10087217B2 (en) | Adeno-associated virus with site-directed mutagenesis and site-directed modification and preparation method and application thereof | |
| Devaney et al. | Clinical review: gene-based therapies for ALI/ARDS: where are we now? | |
| Wagner et al. | Synthetic biology: emerging concepts to design and advance adeno‐associated viral vectors for gene therapy | |
| RU2017125234A (ru) | Конструкции нуклеиновой кислоты и векторы для генотерапии для применения для лечения болезни вильсона и других состояний | |
| Michelfelder et al. | Vectors selected from adeno-associated viral display peptide libraries for leukemia cell–targeted cytotoxic gene therapy | |
| WO2018200419A1 (en) | Viral vectors comprising engineered aav capsids and compositions containing the same | |
| CN117801075A (zh) | 多倍体腺相关病毒载体及其制备和使用方法 | |
| JPWO2020206189A5 (hr) | ||
| CL2020003343A1 (es) | Vectores virales recombinantes con tropismo modificado y usos de los mismos para la introducción dirigida de material genético a células humanas (divisional de la solicitud 201903842) | |
| US20220257760A1 (en) | Cancer-targeted, virus-encoded, regulatable t (catvert) or nk cell (catvern) linkers | |
| US20200407751A1 (en) | Modular system for gene and protein delivery based on aav | |
| JP2023171525A (ja) | Ａａｖキメラ | |
| Killian et al. | Antibody-targeted chromatin enables effective intracellular delivery and functionality of CRISPR/Cas9 expression plasmids | |
| US20210139563A1 (en) | Fusion Proteins Comprising a Cell Surface Marker Specific VHH | |
| Laakkonen et al. | Transcellular targeting of fiber-and hexon-modified adenovirus vectors across the brain microvascular endothelial cells in vitro | |
| Macdonald et al. | Capsid-engineering for central nervous system-directed gene therapy with adeno-associated virus vectors | |
| JPWO2020242984A5 (hr) | ||
| Grandi et al. | Targeting HSV amplicon vectors | |
| CN112166196A (zh) | 大核酸的靶向细胞内递送 | |
| EP4353737A1 (en) | Fusion proteins comprising a cell surface marker specific vhh | |
| US20240124892A1 (en) | Adeno-associated viruses and methods and materials for making and using adeno-associated viruses | |
| CL2022003100A1 (es) | Vectores virales recombinantes con tropismo modificado y sus usos (divisional 201903842) |